Over the past few weeks, Suzlon has aggressively eliminated debt from its heavily levered balance sheet. First, it has divested its holding in Senvion (its German subsidiary) to raise a billion Euros. Second, in a swift affirmation of support for Suzlon, the promoters of Sun Pharma (Dilip Shanghvi and Associates, DSA) are picking up a 23% stake in Suzlon, via a preferential issue of 1 bn shares at Rs 18/sh